Additionally, mice bearing DRG2-depleted melanoma did not respond to anti-PD-1 treatment, and data analysis of a melanoma patient cohort undergoing anti-PD-1 treatment [26] revealed that low DRG2 protein expression correlated with poor clinical response in melanoma patients. Here, DRG2 is linked to melanoma.